FDA Rejects Friedreich's Ataxia Drug Vatiquinone
The FDA declined PTC Therapeutics' vatiquinone for Friedreich's Ataxia, citing insufficient efficacy data and requiring more studies.
NOTRELOAD AI
Viking's Weight-Loss Pill Shows Lower Results
Viking Therapeutics' oral VK2735 achieved up to 12.2% weight loss in a Phase 2 trial, which was below expectations. It is safe, well-tolerated, and has mild gastrointestinal effects.
SoftBank Eyes Intel Chip Foundry Amid AI Expansion
SoftBank's Masayoshi Son met Intel's CEO to discuss acquiring its struggling chipmaking unit. SoftBank has invested $2 billion in Intel, buying shares at $23, making it the sixth-largest shareholder with ~2% ownership.
GoodRx & Novo Nordisk Unlock GLP-1 Access
GoodRx partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499/month to self-paying patients, expanding access for those without adequate insurance. This makes them available at over 70,000 U.S. pharmacies. Hims & Hers down.
TeraWulf Expands Lake Mariner: 160 MW for Fluidstack, Google Boosts Stake
TeraWulf's Lake Mariner campus adds 160 MW for Fluidstack, reaching 360 MW total. Google's backstop hits $3.2B, increasing its stake to 14% in this key AI infrastructure build-out.
Novo's Wegovy Secures Accelerated FDA Approval for MASH
Novo Nordisk's Wegovy (semaglutide) is now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) with liver scarring, a significant advancement for this serious condition.